Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

“…This is corroborated by some preliminary human data, i.e. sotrovimab effectively prevented disease progression in omicron-infected, predominantly severely immunocompromised patients with mild to moderate COVID-19 [ 171 , 172 ]. However, these studies were not placebo-controlled and omicron is known to be associated with less severe COVID-19 overall [ 173 ].…”

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

“…Thus, the global preventive strategy with vaccines, pre-exposure prophylaxis, combined with early therapies once COVID-19 infection is diagnosed appeared to be efficient. While Omicron variants have been associated with less severe diseases than Delta variant, mortality among immunocompromised patients (at least KTR) remains high without adequate preexposure prophylaxis treatment and early treatment[ 11 ].…”

Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19

“…For example, Chavarot et al . 11 reported clinical efficacy of sotrovimab in kidney transplant recipients with Omicron COVID-19; however, the occurrence of the BA.2 variant, which escapes sotrovimab binding, currently limits the use of sotrovimab in clinical practice. 15 In contrast, antivirals have shown persistent in vitro efficacy against COVID-19, independently of the SARS-CoV-2 variant, 16 making these drugs a promising alternative for the treatment of COVID-19.…”

“… 7–9 However, clinical trials evaluating the efficacy of these preventive and curative treatments have been conducted among non-vaccinated, mostly non-immunocompromised, patients prior to the occurrence of the Omicron variant. While the occurrence of the Omicron variant has been associated with reduced severity of COVID-19, 10 recent data show that immunocompromised patients remain at a high risk of morbidity and mortality from COVID-19, possibly due to the lack of vaccine efficacy in this population 11 , 12 and Omicron escape from casirivimab/imdevimab prophylaxis. 13 Whether anti-SARS-CoV-2 preventative and curative targeted treatments are well tolerated and are efficient to decrease morbidity and mortality in immunocompromised patients is unknown.…”